Bristol-Myers Squibb (BMY) Tops Q2 EPS by 40c; raises guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.46, $0.40 better than the analyst estimate of $1.06. Revenue for the quarter came in at $12.27 billion versus the consensus estimate of $11.34 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2025 EPS of $6.35-$6.65, versus the consensus of $6.32. Bristol-Myers Squibb sees FY2025 revenue of $46.5-47.5 billion, versus the consensus of $46.265 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform